ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO609

Long-Term Outcomes of Patients with FSGS: A Multicenter Real-World Evidence (RWE) Study

Session Information

Category: Glomerular Diseases

  • 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics

Authors

  • Poyan-Mehr, Ali, The Permanente Medical Group Inc, Oakland, California, United States
  • Drozd, Alice J., The Permanente Medical Group Inc, Oakland, California, United States
  • Li, Tingting, Washington University in St Louis, St Louis, Missouri, United States
  • Hsu, Raymond K., University of California San Francisco, San Francisco, California, United States
  • Singh, Tripti, University of Wisconsin-Madison, Madison, Wisconsin, United States
  • Messias, Nidia Cordeiro, Washington University in St Louis, St Louis, Missouri, United States
  • Wiegley, Nasim, University of California Davis, Davis, California, United States
  • Jen, Kuang-Yu, University of California Davis, Davis, California, United States
  • Lecker, Stewart H., Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
  • Arora, Swati, Allegheny Health Network, Pittsburgh, Pennsylvania, United States
  • Waguespack, Dia Rose, The University of Texas Health Science Center at Houston John P and Katherine G McGovern Medical School, Houston, Texas, United States
  • Tchakarov, Amanda, The University of Texas Health Science Center at Houston John P and Katherine G McGovern Medical School, Houston, Texas, United States
  • Mendelssohn, Nancy D., The Permanente Medical Group Inc, Oakland, California, United States
  • Mansour, Iyad S. M., Banner - University Medical Center Tucson, Tucson, Arizona, United States
  • Sandhu, Tejwinder S., The Permanente Medical Group Inc, Oakland, California, United States
  • Mena, Jose D., Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
  • Sanchez, Gabriela, The Permanente Medical Group Inc, Oakland, California, United States
  • Yip, Jennifer, The Permanente Medical Group Inc, Oakland, California, United States
  • Sivaswarupan, Mythili, The Permanente Medical Group Inc, Oakland, California, United States
  • Avins, Andrew, The Permanente Medical Group Inc, Oakland, California, United States
Background

FSGS is a common histopathologic lesion in adult patients with nephrotic syndrome. We report on one of the most extensive observational studies of FSGS to identify predictors of long-term outcomes.

Methods

Nine centers enrolled 723 patients with FSGS of primary, genetic, or unknown etiology between 01/01/2000 and 08/01/2021. The GlomCon Research Consortium developed data definitions, collection instruments and study protocol.

Results

Clinical and biopsy characteristics (Table 1) were evaluated based on treatment history. Figure 1 and Table 2 show outcomes at 1, 3, and 5 years and time to events. Several statistically and clinically significant differences exist between immunosuppressive therapy (IST) and no IST groups.

Conclusion

The overall risk of ESKD and death is substantial. Additional analysis is being conducted to identify independent factors (clinical, treatment, and biopsy characteristics) associated with patient outcomes, predictors of IST response, and those most at risk for CKD progression, ESKD, and death.

Funding

  • Commercial Support – Travere Therapeutics